EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

SYNGAP1 Syndrome and the Brain Gene Registry

Melissa R Greco, Maya Chatterjee, Alexa M Taylor iD, Andrea L Gropman

Genes · 2025

DOI: 10.3390/genes16040405 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, 2025. Verfasst von Melissa R Greco und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurogenetics and Neurodevelopmental Pediatrics, Children's National Hospital, Washington, DC 20010, USA. Hauptthemen laut MEDLINE: ras GTPase-Activating Proteins, Registries, Neurodevelopmental Disorders, Brain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NHGRI NIH HHS, This research was funded by the NIH..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The human brain relies on complex synaptic communication regulated by key genes such as SYNGAP1. SYNGAP1 encodes the GTPase-Activating Protein (SYNGAP), a critical synaptic plasticity and neuronal excitability regulator. Impaired SYNGAP1 function leads to neurodevelopmental disorders (NDDs) characterized by intellectual disability (ID), epilepsy, and behavioral abnormalities. These variants disrupt Ras signaling, altering AMPA receptor transport and synaptic plasticity and contributing to cognitive and motor difficulties. Despite advancements, challenges remain in defining genotype–phenotype correlations and distinguishing SYNGAP1-related disorders from other NDDs, which could improve underdiagnosis and misdiagnosis. Brain Gene Registry: The Brain Gene Registry (BGR) was established as a collaborative initiative, consolidating genomic and phenotypic data across multiple research centers. This database allows for extensive analyses, facilitating improved diagnostic accuracy, earlier interventions, and targeted therapeutic strategies. The BGR enhances our understanding of rare genetic conditions and is critical for advancing research on SYNGAP1-related disorders.

Conclusions

While no FDA-approved treatments exist for SYNGAP1-related disorders, several therapeutic approaches are being investigated. These include taurine supplementation, ketogenic diets, and molecular strategies such as antisense oligonucleotide therapy to restore SYNGAP1 expression. Behavioral and rehabilitative interventions remain key for managing developmental and cognitive symptoms. Advancing research through initiatives like the BGR is crucial for refining genotype–phenotype associations and developing precision medicine approaches. A comprehensive understanding of SYNGAP1-related disorders will improve clinical outcomes and patient care, underscoring the need for continued interdisciplinary collaboration in neurodevelopmental genetics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ras GTPase-Activating ProteinsRegistriesNeurodevelopmental DisordersBrainIntellectual DisabilityHumansEpilepsy

Stichwörter der Autor:innen

SYNGAP1brain gene registryintellectual disabilityneurodevelopmental disorder

Substanzen

ras GTPase-Activating ProteinsSYNGAP1 protein, human

Autor:innen und Institutionen

  • Division of Neurogenetics and Neurodevelopmental Pediatrics, Children's National Hospital, Washington, DC 20010, USA.
  • St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

ORCID-Profile: Alexa M Taylor

Förderung

  • NCATS NIH HHS
  • NHGRI NIH HHS
  • This research was funded by the NIH.
  • NIH

Zitieren

APA

Greco, M. R., Chatterjee, M., Taylor, A. M., & Gropman, A. L. (2025). SYNGAP1 Syndrome and the Brain Gene Registry. Genes. https://doi.org/10.3390/genes16040405

Vancouver

Greco MR, Chatterjee M, Taylor AM, Gropman AL. SYNGAP1 Syndrome and the Brain Gene Registry. Genes. 2025. doi:10.3390/genes16040405

BibTeX
@article{Greco2025,
  author = {Greco, Melissa R and Chatterjee, Maya and Taylor, Alexa M and Gropman, Andrea L},
  title = {SYNGAP1 Syndrome and the Brain Gene Registry},
  journal = {Genes},
  year = {2025},
  doi = {10.3390/genes16040405}
}
Kostenlos starten →